Author(s):
Haidar A Abdulamir, Rasha K. J. Ali, Ahmed Hameed Al Saeedi
Email(s):
haider.adnan@hilla-unc.edu.iq
DOI:
10.52711/0974-4150.2026.00068 
Address:
Haidar A Abdulamir1*, Rasha K. J. Ali2, Ahmed Hameed Al Saeedi1
1College of Pharmacy, University of Hilla, Babylon 51001, Iraq.
2Department of Pharmacy, Al-Warka University College, Basra, Iraq.
*Corresponding Author
Published In:
Volume - 19,
Issue - 5,
Year - 2026
ABSTRACT:
Gaucher disease (GD) is the most common lysosomal storage disorder, resulting from an inherited deficiency of the enzyme glucocerebrosidase with an accumulation of glucocerebroside within macrophages of the reticuloendothelial system. Since the introduction of enzyme replacement therapy (ERT), reproducible biomarkers have become essential for GD diagnosis and monitoring the treatment. For that, plasma chitotriosidase (ChT), an enzyme that secreted almost exclusively by activated macrophages, has emerged as the most powerful and most extensively validated. This review summarizes ChT biology, the pathophysiological basis of its elevation in GD, and the current evidence for its use in the diagnosis and, in particular, the monitoring and follow-up of enzyme replacement therapy in GD patients. Literatures demonstrated that ChT activity is elevated significantly in untreated GD patients relative to healthy individuals, which become declined sharply and progressively with ERT, most markedly during the first 6-12 months of treatment accompanying the reduction in visceral and hematological disease burden. Receiver Operating Characteristic (ROC) curve analyses across multiple cohorts, have shown that ChT achieves near-perfect sensitivity and specificity, both for distinguishing patients from controls and for differentiating successive stages of treatment, outperforming other candidate biomarkers such as tartrate-resistant acid phosphatase, angiotensin-converting enzyme, and ferritin. Important limitations remain, principally a common null polymorphism in the CHIT1 gene that abolishes enzymatic activity in a subset of the population, and substrate inhibition at high enzyme concentrations, both of which can complicate interpretation. Despite these caveats, ChT remains the single most useful biochemical parameter currently available for the routine monitoring and follow-up of enzyme replacement therapy in Gaucher disease and is recommended as a core component of the biomarker panel used in the long-term care of these patients.
Cite this article:
Haidar A Abdulamir, Rasha K. J. Ali, Ahmed Hameed Al Saeedi. Chitotriosidase Role in the Monitoring and Follow-up of Treatment in Gaucher Disease: A Review. Asian Journal of Research in Chemistry. 2026; 19(5):471-4. doi: 10.52711/0974-4150.2026.00068
Cite(Electronic):
Haidar A Abdulamir, Rasha K. J. Ali, Ahmed Hameed Al Saeedi. Chitotriosidase Role in the Monitoring and Follow-up of Treatment in Gaucher Disease: A Review. Asian Journal of Research in Chemistry. 2026; 19(5):471-4. doi: 10.52711/0974-4150.2026.00068 Available on: https://www.ajrconline.org/AbstractView.aspx?PID=2026-19-5-9
REFERENCES:
1. Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol. 2005; 129(2): 178-188.
2. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 2008; 372(9645): 1263-1271.
3. Beutler E, Nguyen NJ, Henneberger MW, Smolec JM, McPherson RA, West C, et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet. 1993; 52(1): 85-88.
4. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002; 113(2): 112-119.
5. Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther. 2012; 6: 81-106.
6. Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 2004; 103(1): 33-39.
7. Mutaz Sabah A, Khdhair Abbas K, Shaymaa Mohammed Salih. The Relationship between Serum Level of Ferritin and Cardiac Troponin T (cTnT) in Children with Major Beta-Thalassemia. Research J. Pharm. and Tech. 2019; 12(4): 1713-1716.
8. Kanneganti M, Kamba A, Mizoguchi E. Role of chitotriosidase (chitinase 1) under normal and disease conditions. J Epithel Biol Pharmacol. 2012; 5: 1-9.
9. Irún P, Alfonso P, Aznarez S, Giraldo P, Pocovi M. Chitotriosidase variants in patients with Gaucher disease. Implications for diagnosis and therapeutic monitoring. Clin Biochem. 2013; 46(18): 1804-1807.
10. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease. J Clin Invest. 1994; 93(3): 1288-1292.
11. Awadh AI. The Role of Lipid Profile Assessment in Monitoring the effect of Imiglucerase in Children with Gaucher Disease. Res J Pharm Technol. 2023; 16(2): 573-0.
12. Abdulamir HA,Aldafaay AAA, Al-Shammari AH. The Role of Liver Function Tests in Monitoring the effect of Enzyme Replacement Therapy in Children with Gaucher Disease. Res J Pharm Technol. 2022; 15(8): 3490-6.
13. Guo Y, He W, Boer AM, Wevers RA, de Bruijn AM, Groener JE, et al. Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J Inherit Metab Dis. 1995; 18(6): 717-722.
14. Al-Kinani ZA, Ali SH. Serum Chitotriosidase level as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis among the Iraqi children. Iraqi Journal of Pharmaceutical Sciences. 2021; 30(1): 270-6.
15. Walia MS. Performance Analysis of Feature Extraction Techniques for Iris Pattern Recognition System. Research J. Engineering and Tech. 2017; 8(4): 431-435.
16. Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J Intern Med. 2013; 4(2): 627-635.
17. Czartoryska B, Tylki-Szymańska A, Górska D. Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT). Clin Biochem. 1998 Jul; 31(5): 417-20.
18. Ries M, Schaefer E, Lührs T, Mani L, Kuhn J, Vanier MT, Krummenauer F, Gal A, Beck M, Mengel E. Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children with Gaucher disease and Niemann-Pick disease type A/B and C. J Inherit Metab Dis. 2006 Oct; 29(5): 647-52. doi: 10.1007/s10545-006-0363-3. Epub 2006 Jul 27. PMID: 16972172.
19. Bennett D, Cameli P, Lanzarone N, Carobene L, Bianchi N, Fui A, Rizzi L, Bergantini L, Cillis G, d'Alessandro M, Mazzei MA, Refini RM, Sestini P, Bargagli E, Rottoli P. Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis. Respir Res. 2020 Jan 6; 21(1): 6. doi: 10.1186/s12931-019-1263-z. Erratum in: Respir Res. 2020 Jan 29;21(1):34. doi: 10.1186/s12931-020-1303-8. PMID: 31906975; PMCID: PMC6945638.
20. Szymańska-Rożek P, Czartoryska B, Kleinotiene G, Lipiński P, Tylki-Szymańska A, Ługowska A. A 20-Year Longitudinal Study of Plasma Chitotriosidase Activity in Treated Gaucher Disease Type 1 and 3 Patients-A Qualitative and Quantitative Approach. Biomolecules. 2023 Feb 24; 13(3): 436. doi: 10.3390/ biom13030436. PMID: 36979371; PMCID: PMC10046580.
21. Linari S, Castaman G. Clinical manifestations and management of Gaucher disease. Clin Cases Miner Bone Metab. 2015; 12(2): 157-164.
22. Sumarac Z, Suvajdžić N, Ignjatović S, Majkić-Singh N, Janić D, Petakov M, et al. Biomarkers in Serbian patients with Gaucher disease. Clin Biochem. 2011; 44(12): 950-954.
23. Aldafaay AAA, Abdulamir HA, Abdulhussain HA, Badry AS, Abdulsada AK. The use of Urinary α-amylase level in a diagnosis of Chronic renal failure. Res J Pharm Technol. 2021; 14(3): 1597-1600.
24. Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017; 18(2): 441
25. Smid BE, Ferraz MJ, Verhoek M, Mirzaian M, Wisse P, Overkleeft HS, et al. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients. Orphanet J Rare Dis. 2016; 11: 28.
26. Aslan SK, Ozel Z. Compatibility of Charge Nurse Self-Assessments and Executive Nurse Evaluations: A 5-Year Multi-Center Study. International Journal of Advances in Nursing Management. 2024; 12(4): 151-7.
27. Raju CP, Babu GP, Sowjanya M, Ramayyappa M. Evaluation of Cancer Bio-markers through Hyphenated Analytical Techniques. Asian J Pharm. Anal. 2021; 11(3): 235-2.
28. Khatri M, Dhar S, Ven P, Singh A. Understanding the Pharmacological Mechanisms of Anticancer Resistance: A Multifaceted Challenge in Cancer Treatment. Asian J Pharm Res. 2024; 14(2): 183-7.
29. Mahajan S, Dave H, Bothe S, Mahpatra D, Sonawane S, Kshirsagar S, et al. Objective Monitoring of Cardiovascular Biomarkers using Artificial Intelligence (AI). Asian J Pharm Res. 2022; 12(3): 229-4.
30. Wale S, Lade S, Dalvi S, Katakdhond D, Desai A, Karnkoti A, et al. Smart Bandage: A Targeted Treatment and Wound Monitoring Device. Int J Technol. 2026; 16(1): 73-7.
31. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007; 82(8): 697-701.
32. Chen M, Wang J. Gaucher disease: review of the literature. Arch Pathol Lab Med. 2008; 132(5): 851-853.